Generally, KRAS and BRAF mutations are mutually exclusive, moreover, BRAF indicates poorer prognosis for mCRC patients treated with anti-EGFR therapy16, while the role of BRAF in other cancer stage is still unclear, reported studies did not sustain accordance about this issue17, 18, 19, 20. The gene discussed is KRAS; the disease is cancer.